Aquestive Completes $150 Million Recapitalization, Q1 Earnings to be Released After Market Close

Aquestive Therapeutics released its financial report for the first quarter of 2026 in the early morning of May 14th, Beijing time, with a conference call scheduled for 8 PM Beijing time on May 14th. Consensus expectations on Wall Street project Q1 revenue to be around $10.9 million, with an EPS expectation of a loss of $0.14.

The day before the financial report, the company disclosed a key adjustment to its capital structure. On May 12th, Aquestive announced the completion of a $150 million debt refinancing with Oaktree Capital Management, with an initial $55 million already in place, primarily to repay the original principal amount of $45 million loan and related fees. The new agreement is a five-year pure interest structure, with principal repayment at maturity, and no pressure on principal repayment for the next three years.

The financing agreement is designed to be released in batches. After the FDA approval of Anaphylm, the company can obtain an additional $20 million; upon reaching certain sales milestones, another $25 million will be released; the final tranche, up to $50 million, requires mutual confirmation. CEO Daniel Barber stated that this refinancing simultaneously meets the pre-approval conditions under the strategic financing agreement with RTW Investments, paving the way for the potential commercialization of Anaphylm with funds.

Anaphylm is the company's most core pipeline asset at present, an adrenaline prodrug in sublingual film form for the treatment of severe allergic reactions and anaphylactic shock. The company completed a Type A meeting with the FDA on March 30th, obtaining clear feedback on the design of pharmacokinetic studies and human factor studies, reiterating the intention to resubmit the NDA in Q3 2026, with plans to submit applications in Canada and the European Union within the year.

On the revenue side, Aquestive's base comes from PharmFilm licensing business, with four commercialized products sold by licensees across six continents worldwide, and the company acts as the exclusive manufacturer to collect licensing fees and manufacturing revenue. This CDMO model provides relatively stable cash flow, but on a limited scale, which is difficult to cover ongoing R&D expenditures.

It is worth noting that several law firms have recently filed a securities class action lawsuit against AQST, with a deadline for the lawsuit being May 4th, involving allegations of investor damage compensation. This legal risk is one of the current factors putting pressure on the stock price, which investors need to pay attention to.

The core focus of tonight's conference call is threefold: whether Q1 actual revenue can reach the expected $10.9 million, the latest statement from management on the Anaphylm Q3 submission timeline, and the updated guidance on the annual cash consumption rhythm after the refinancing is completed.